Loading stock data…
Curis, Inc. (CRIS)
$1.27-0.08 (-5.93%)
Market ClosedLast close Sep 8
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Curis, Inc. in the Healthcare sector is trading at $1.27 with a market capitalization of $3M. Wall Street consensus targets $42.67 (3 analysts), implying a +3259.6% move over the next 12 months. The stock is currently near its 52-week low of $1.26, remaining 90.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 6 is oversold, raising the odds of a near-term bounce. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +3259.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 6) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $1.14M↓ | $3.18M↑ | $2.75M |
| Gross Profit | $0 | $0↓ | $1.14M↓ | $3.16M↑ | $2.73M |
| Operating Income | -$9.94M↑ | -$11.52M↓ | -$7.57M↓ | -$6.92M↑ | -$8.25M |
| Net Income | -$8.58M↑ | -$24.20M↓ | $19.36M↑ | -$7.73M↑ | -$8.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.08M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.35
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-450.54%
Volume
Today's trading volume
144,478
Recent News
Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework
The fair value price target for Curis has been reset from US$280.00 to US$42.67, which represents a very large downward adjustment in the modeled target level. Analysts link this shift to updated assumptions around emavusertib and the TakeAim chronic lymphocytic leukemia study, where price targets now reflect explicit probabilities of success, peak sales estimates and timing. As you read on, you will see how this evolving narrative around Curis might influence the way you track the stock from...
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance. The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted...
Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus
Curis is back in focus after analysts lifted their fair value estimate from US$14 to US$280, a very large reset in what they consider a reasonable long term outcome for the stock. This shift is being framed around improved leadership and a heavier emphasis on direct to consumer channels, while more cautious voices question how much of that story is already reflected in the higher figure. Read on to see how this evolving narrative could shape expectations and what to watch as new information...
Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)
New lymphoma results support development programmeCuris, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the biotechnology company released encouraging updated clinical data for emavusertib in patients with Primary CNS Lymphoma (PCNSL) and raised enrollment expectations for its Chronic Lymphocytic Leukemia (CLL) study.
Curis opens 11 sites for emavusertib combo in TakeAim CLL trial
Curis plans to dose the initial five patients by the end of July 2026, with data anticipated in December 2026.